Literature DB >> 12500109

Alcohol unmasks simian immunodeficiency virus-induced cognitive impairments in rhesus monkeys.

Peter J Winsauer1, Joseph M Moerschbaecher, Ian N Brauner, Jeanette E Purcell, Jack R Lancaster, Gregory J Bagby, Steve Nelson.   

Abstract

BACKGROUND: Alcohol and human immunodeficiency virus (HIV) produce similar neuropathological profiles, including loss of neurons in the frontal cortex. Additionally, HIV-positive patients with a history of alcohol abuse have greater neurologic deficits, and chronic alcohol abuse produces electrophysiological deficits earlier in the HIV disease process. Few studies, preclinical or clinical, have examined whether alcohol administration exacerbates the neuropsychological deficits in subjects with lentiviruses such as HIV.
METHODS: To examine the combined effects of alcohol and immunodeficiency viruses (IVs) on neuropsychological functioning, four groups of young adult rhesus monkeys trained to respond under two complex behavioral tasks were administered ethanol 4 days per week via an intragastric catheter for 3 months and then infected with simian immunodeficiency virus (SIV). Behavioral testing after SIV inoculation was conducted in each group (-ethanol [EtOH]/-SIV, -EtOH/+SIV, +EtOH/-SIV, and +EtOH/+SIV) on days when alcohol was not administered to avoid a direct confound and on several occasions when ethanol or sucrose was administered as a probe of the effect of alcohol alone and the effect of caloric supplementation on the food-maintained tasks, respectively.
RESULTS: During the days of the week when ethanol was not administered, little or no disruption was observed in either response rate or the percentage of errors (accuracy) across the different treatment groups. In contrast, behavioral testing during alcohol administration revealed that subjects in the various treatment groups had different susceptibilities to ethanol administration. As expected, a two-way ANOVA (ethanol condition, SIV condition) indicated there were significant main effects of ethanol on both response rate and percent errors in both behavioral tasks, but it also indicated there was a significant interaction between ethanol administration and SIV infection on the accuracy of responding in the acquisition (learning) task. In addition, the main effect of SIV on percent errors was in the performance task.
CONCLUSIONS: The fact that alcohol administration in SIV-infected monkeys produced greater behavioral deficits than either alcohol or SIV alone further strengthens the supposition that IVs adversely affect neural substrates involved in cognition and that the adverse effects of many central nervous system drugs may be enhanced in IV-infected individuals.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12500109     DOI: 10.1097/01.ALC.0000042171.80435.F1

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  20 in total

1.  Comparison of the behavioral and cardiovascular effects of mephedrone with other drugs of abuse in rats.

Authors:  Kurt J Varner; Kyle Daigle; Peter F Weed; Peter B Lewis; Sarah E Mahne; Ananthakrishnan Sankaranarayanan; Peter J Winsauer
Journal:  Psychopharmacology (Berl)       Date:  2012-09-13       Impact factor: 4.530

2.  Acute ethanol reduces reversal cost in discrimination learning by reducing perseverance in adolescent rhesus macaques.

Authors:  M Jerry Wright; Courtney Glavis-Bloom; Michael A Taffe
Journal:  Alcohol Clin Exp Res       Date:  2013-01-08       Impact factor: 3.455

3.  Acute exposure to ethanol potentiates human immunodeficiency virus type 1 Tat-induced Ca(2+) overload and neuronal death in cultured rat cortical neurons.

Authors:  Eugen Brailoiu; G Cristina Brailoiu; Giuseppe Mameli; Antonina Dolei; Bassel E Sawaya; Nae J Dun
Journal:  J Neurovirol       Date:  2006-02       Impact factor: 2.643

Review 4.  Behavioral, Metabolic, and Immune Consequences of Chronic Alcohol or Cannabinoids on HIV/AIDs: Studies in the Non-Human Primate SIV Model.

Authors:  Patricia E Molina; Angela M Amedee; Peter Winsauer; Steve Nelson; Gregory Bagby; Liz Simon
Journal:  J Neuroimmune Pharmacol       Date:  2015-03-21       Impact factor: 4.147

5.  Tolerance to chronic delta-9-tetrahydrocannabinol (Δ⁹-THC) in rhesus macaques infected with simian immunodeficiency virus.

Authors:  Peter J Winsauer; Patricia E Molina; Angela M Amedee; Catalin M Filipeanu; Robin R McGoey; Dana A Troxclair; Edith M Walker; Leslie L Birke; Curtis Vande Stouwe; Jessica M Howard; Stuart T Leonard; Joseph M Moerschbaecher; Peter B Lewis
Journal:  Exp Clin Psychopharmacol       Date:  2011-04       Impact factor: 3.157

Review 6.  Biomedical consequences of alcohol use disorders in the HIV-infected host.

Authors:  Patricia E Molina; Gregory J Bagby; Steve Nelson
Journal:  Curr HIV Res       Date:  2014       Impact factor: 1.581

Review 7.  Chronic alcohol abuse and HIV disease progression: studies with the non-human primate model.

Authors:  Angela M Amedee; Whitney A Nichols; Spencer Robichaux; Gregory J Bagby; Steve Nelson
Journal:  Curr HIV Res       Date:  2014       Impact factor: 1.581

8.  Chronic alcohol consumption generates a vulnerable immune environment during early SIV infection in rhesus macaques.

Authors:  Maria Cecilia G Marcondes; Debbie Watry; Michelle Zandonatti; Claudia Flynn; Michael A Taffe; Howard Fox
Journal:  Alcohol Clin Exp Res       Date:  2008-07-09       Impact factor: 3.455

9.  Callosal Compromise Differentially Affects Conflict Processing and Attentional Allocation in Alcoholism, HIV, and Their Comorbidity.

Authors:  Tilman Schulte; Eva M Müller-Oehring; Harold Javitz; Adolf Pfefferbaum; Edith V Sullivan
Journal:  Brain Imaging Behav       Date:  2008       Impact factor: 3.978

10.  Neuropsychological Assessment Battery-Screening Module (S-NAB): performance in treatment-seeking cocaine users.

Authors:  Daniela L Cannizzaro; Jennifer C Elliott; Malka Stohl; Deborah S Hasin; Efrat Aharonovich
Journal:  Am J Drug Alcohol Abuse       Date:  2014-06-20       Impact factor: 3.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.